John D. Imig, PhD
- Pharmacology and Toxicology
BA, Biology, Blackburn College, 1985
The Imig laboratory is dedicated to understanding the mechanisms by which certain fatty acids “eicosanoids” influence kidney and cardiovascular function. Research in the laboratory focuses on kidney and blood vessel function in normal and disease states. We have developed novel eicosanoid-based drugs to treat diseases including hypertension, stroke, heart attacks, diabetes, and kidney diseases. These novel drugs have tremendous potential as a therapy for cardiovascular and kidney diseases.
Hypertension, Diabetes, & Metabolic Syndrome
Obesity, hypertension, and type 2 diabetes are major contributing factors to the increase in the number of patients that have cardiovascular events and end-organ damage. Metabolic syndrome is a serious health problem worldwide that has two major underlying causes, abdominal obesity and insulin resistance that clusters with other cardiovascular risk factors. Endothelial dysfunction, inflammation, oxidative stress, and insulin resistance are interrelated and increase the risk for cardiovascular events and end-organ damage in hypertension, diabetes, and metabolic syndrome. Moreover, eicosanoids are altered in these diseases and contribute to endothelial function, inflammation, oxidative stress, and insulin resistance. In particular, cyclooxygenase (COX), epoxygenase, and soluble epoxide hydrolase (sEH) metabolites are altered in disease states and contribute to the progression of disease processes. We have identified a distinct synergy between COX-2 and sEH inhibitors on the eicosanoid metabolome. This finding resulted in the development and synthesis of COX-2/sEH inhibitors that demonstrate great promise as a novel therapeutic approach for treating hypertension, diabetes, and metabolic syndrome. The goals of this project will identify novel ways to therapeutically target the eicosanoid metabolome for improving cardiovascular, renal, and pancreatic function in hypertension, diabetes, and metabolic syndrome.
Chronic Kidney Disease (CKD)
CKD from any cause is a serious public health problem; an estimated 33 million Americans have kidney disease. Hypertension, obesity, diabetes, infections, and genetic disease can lead to CKD. Other at risk groups include veterans and first-responders exposed to radiation, either on the battlefield, from terrorist events, or as a result of industrial accidents; these people risk developing radiation nephropathy and ultimately CKD. CKD also occurs in 15% of hematopoietic stem cell transplant (HSCT) patients, and has been clearly linked to irradiation at the time of the HSCT. HSCT is increasingly used worldwide for the treatment of cancer, and over 50,000 people per year now undergo HSCT. Long-term survival after HSCT is now near 50%, which means that more people will have late effects, which include CKD. CKD due to radiation also occurs after radionuclide therapy for cancer. Our laboratory has identified and developed epoxyeicosatrienoic acid (EET) analogs that show promise as a novel therapeutic approach for CKD. EET analogs have anti-inflammatory, anti-apoptotic, and anti-oxidative activities that will translate into a novel therapeutic for CKD. Consequently, we will test EET analogs as a new and better treatment for CKD.
Acute Kidney Injury (AKI)
Acute kidney injury (AKI), also known as, nephrotoxicity, occurs after exposure to drugs, other medical procedures, or exogenous toxins. The mortality rate for AKI patients is 30-60% and 20-30% of the survivors of AKI will develop CKD. There are limited options for treating AKI and these options currently include fluid and blood pressure management via drugs and intravenous fluids or hemodialysis. EETs have biological actions that implicate them as important contributors to kidney function. Over the past decade it has become increasingly apparent that EETs have a myriad of kidney actions and the overwhelming majority of these biological actions are kidney protective. Our innovation is based on the expected outcome that EET analogs have unique kidney actions that make them a novel target for developing treatments to prevent and treat AKI. Recent studies have demonstrated that EET analogs prevent AKI and renal damage that occurs with the anti-cancer drug cisplatin. This research project will identify novel ways to therapeutically target EETs for treating AKI.
(Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Blöcher R, Kircher T, Savchuk O, Proschak E, Imig JD.) Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472 PMID: 32569747 SCOPUS ID: 2-s2.0-85086773315 06/23/2020
(Gawrys O, Husková Z, Baranowska I, Walkowska A, Sadowski J, Kikerlová S, Vaňourková Z, Honetschlägerová Z, Škaroupková P, Červenka L, Falck JR, Imig JD, Kompanowska-Jezierska E.) J Hypertens. 2020 Sep;38(9):1802-1810 PMID: 32384390 SCOPUS ID: 2-s2.0-85089302292 05/10/2020
(Imig JD, Jankiewicz WK, Khan AH.) Hypertension. 2020 Jul;76(1):3-15 PMID: 32475311 PMCID: PMC7448548 SCOPUS ID: 2-s2.0-85086345972 06/02/2020
(Imig JD.) Physiol Res. 2019 10 25;68(5):695-704 PMID: 31475560 PMCID: PMC6941753 SCOPUS ID: 2-s2.0-85074674063 09/03/2019
(Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D.) Biochem Pharmacol. 2019 08;166:212-221 PMID: 31129048 PMCID: PMC6939295 SCOPUS ID: 2-s2.0-85066443159 05/28/2019
(Widiapradja A, Manteufel EJ, Dehlin HM, Pena J, Goldspink PH, Sharma A, Kolb LL, Imig JD, Janicki JS, Lu B, Levick SP.) Sci Rep. 2019 07 29;9(1):11004 PMID: 31358823 PMCID: PMC6662794 SCOPUS ID: 2-s2.0-85069892832 07/31/2019
(Neckář J, Hye Khan MA, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A, Falck JR, Campbell WB, Sedláková L, Škutová Š, Olejníčková V, Gregorovičová M, Sedmera D, Kolář F, Imig JD.) Clin Sci (Lond). 2019 04 30;133(8):939-951 PMID: 30979784 PMCID: PMC6492034 SCOPUS ID: 2-s2.0-85064975365 04/14/2019
Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats.
(Čertíková Chábová V, Kujal P, Vaňourková Z, Škaroupková P, Sadowski J, Kompanowska-Jezierska E, Tesař V, Hammock B, Imig J, Maxová H, Červenka L, Vaněčková I.) Kidney Blood Press Res. 2019;44(6):1493-1505 PMID: 31770762 SCOPUS ID: 2-s2.0-85075787703 11/27/2019
(Vacková Š, Kikerlová S, Melenovsky V, Kolář F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Červenka L.) Kidney Blood Press Res. 2019;44(4):792-809 PMID: 31430751 SCOPUS ID: 2-s2.0-85071709898 08/21/2019
(Hye Khan MA, Stavniichuk A, Sattar MA, Falck JR, Imig JD.) Front Pharmacol. 2019;10:512 PMID: 31133860 PMCID: PMC6523399 05/28/2019
(Hrdlička J, Neckář J, Papoušek F, Husková Z, Kikerlová S, Vaňourková Z, Vernerová Z, Akat F, Vašinová J, Hammock BD, Hwang SH, Imig JD, Falck JR, Červenka L, Kolář F.) Front Pharmacol. 2019;10:159 PMID: 30881303 PMCID: PMC6406051 03/19/2019
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
(Vacková Š, Kopkan L, Kikerlová S, Husková Z, Sadowski J, Kompanowska-Jezierska E, Hammock BD, Imig JD, Táborský M, Melenovský V, Červenka L.) Front Pharmacol. 2019;10:18 PMID: 30728778 PMCID: PMC6351500 02/08/2019